Ventures

Epilepsy causes uncontrolled seizures, greatly reducing quality of life and sometimes leading to early death. Over 50 million people worldwide have epilepsy, but only two-thirds respond to medication. For those with drug-resistant epilepsy, treatment options are limited and often ineffective. MIR Therapeutics is developing a new gene therapy to provide lasting and powerful seizure control for drug-resistant epilepsy patients. Their therapy delivers microRNA-335 to the affected brain regions using an AAV9 viral vector, which helps control hyperexcitability by regulating voltage-gated sodium channels. This results in fewer and less severe seizures.

Allergios revolutionizes allergy diagnosis by directly visualizing the allergic response in patient blood, offering a more accurate alternative to current tests like skin prick and IgE blood tests. Additionally by analyzing how blood serum reacts to allergens. With its disposable chip, optical reader, and AI-based analysis software, Allergios helps millions of allergy sufferers worldwide access timely and effective treatment options.

Aspect Neuroprofiles is tackling the challenges of diagnosing and treating Autism Spectrum Disorder (ASD) by combining EEG technology with Artificial Intelligence. Their method objectively measures brain activity related to ASD, improving diagnosis accuracy and predicting treatment effectiveness. This approach aims to shift from subjective assessments to objective physiological measurements, offering hope for millions affected by ASD and mental health issues.

StarTric, created by cardiovascular experts, developed a new, less invasive device to fix a serious heart valve problem, Tricuspid Regurgitation (TR). Addressing Tricuspid Regurgitation (TR), a severe condition with high mortality rates, StarTric's device offers a safer alternative to open-heart surgery. The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique, aiming to provide effective treatment to millions of TR patients worldwide who currently lack suitable options.

Aetherus tackles COPD, a debilitating lung disease, with their portable, non-invasive (pNIV) device. This device offers instant relief from breathlessness, improving patients' daily lives without adding to treatment regimens or causing side effects. By empowering patients to manage breathlessness anytime, anywhere, the pNIV device enhances COPD management and quality of life. This not only benefits patients but also alleviates the burden on healthcare systems, families, employers, and society at large.

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.

Rare diseases often lead to years of diagnostic odyssey and immense patient suffering. Therefore Genorare is set to dramatically shorten this diagnostic journey for individuals with rare diseases. Genorare's platform enables real-time, secure analysis of genomic, clinical, and phenotypic data using Large Language Models, predictive analytics, and Fully Homomorphic Encryption. A key innovation is the use of Fully Homomorphic Encryption, a next-generation privacy technology that allows for advanced analysis while ensuring patient data remains completely secure, promising a new standard of care for the rare disease community.

HapticHeart Solutions is revolutionizing cardiac procedures by giving cardiologists a "sense of touch" during catheter-based surgeries. These surgeries, which are becoming more complex, often require delicate maneuvers inside the heart. Their wearable device translates signals from the cath lab into tactile feedback, allowing cardiologists to feel what's happening inside the patient's heart. This helps them navigate catheters more effectively and focus on critical aspects of the procedure, leading to safer and more efficient surgeries with better outcomes for patients.